Long-term treatment of osteoporosis in postmenopausal women: A review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)

Current Medical Research and Opinion

Volumn 28, Issue 3, 2012, Pages 475-491

  Cooper, C ^a,b   Reginster, J Y ^c   Cortet, B ^d   Diaz Curiel, M ^e   Lorenc, R S ^f   Kanis, J A ^g   Rizzoli, R ^h  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bisphosphonate; Calcium; Denosumab; Fracture; Long term treatment; Osteoporosis; SERM; Strontium ranelate; Vitamin D

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; INCADRONIC ACID; LASOFOXIFENE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BREAST CANCER; CALCIUM INTAKE; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; ENDOMETRIUM POLYP; FEMUR SUBTROCHANTERIC FRACTURE; FLATULENCE; FRACTURE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; IRON ABSORPTION; JAW OSTEONECROSIS; LEG CRAMP; LONG TERM CARE; MEDICAL SOCIETY; MORTALITY; NAUSEA; OSTEOARTHRITIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH PAIN; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VERTEBRA MALFORMATION;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES; VITAMIN D;

EID: 84858247953     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.663750     Document Type: Review

References (132)

1. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its implications. Available at: Www.iofbonehealth.org/facts- and-statistics. html [Last accessed 10 August 2009]
2. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-18
3. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
5. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008;44:2122-32
6. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008; 359:1618-20
7. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Longterm Extension (FLEX): A randomized trial. JAMA 2006;296:2927-38
8. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-99
9. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011;89:91-104
10. Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: A retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010;21:1181-7
11. Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20:1912-20
12. Briot K, Tremollieres F, Thomas T, et al. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007; 74:24-31
13. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: Results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95
14. Ensrud KE, Barrett-Connor EL, Schwartz AV, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial Long-term Extension. J Bone Miner Res 2004;19:1259-69
15. Reginster JY, Bruyere O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. Bone 2009;45:1059-64
16. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
17. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
18. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-5
19. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
20. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: Six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011;96:394-402
21. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 2003; 32:120-6
22. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
23. Prince RL, Devine A, Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure: Results of a 5-year, double-blind, placebo- controlled trial in elderly women. Arch Intern Med 2006;166:869-75
24. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:3109-15
25. Devogelaer JP, Brown JP, Burckhardt P, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 2007; 18:1211-18
26. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
27. De Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22:567-76
28. Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351-63
29. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 2011; doi: 10.1002/jbmr.1479. [Epub ahead of print]
30. Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2011; [Epub ahead of print]
31. Rizzoli R, Boonen S, Brandi ML, et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008;42:246-9
32. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Available at: Www.iom.edu/vitamind [Last accessed 14 September 2011]
33. Rizzoli R. Nutrition: Its role in bone health. Best Pract Res Clin Endocrinol Metab 2008;22:813-29
34. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: A meta-analysis of randomised controlled trials. BMJ 2009;339:b3692
35. Ireland P, Fordtran JS. Effect of dietary calcium and age on jejunal calcium absorption in humans studied by intestinal perfusion. J Clin Invest 1973;52:2672-81
36. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1-34
37. Bischoff-Ferrari HA, Can U, Staehelin HB, et al. Severe vitamin D deficiency in Swiss hip fracture patients. Bone 2008;42:597-602
38. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42
39. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308: 1081-2
40. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6
41. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet 2007; 370:657-66
42. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: A meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:551-61
43. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: Evidence from a comparative meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92:1415-23
44. Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, et al. Calcium intake and hip fracture risk in men and women: A meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr 2007;86: 1780-90
45. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebocontrolled trial. Lancet 2005;365:1621-8
46. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA 2010;303:1815-22
47. The DIPART Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:b5463
48. Krall EA, Wehler C, Garcia RI, et al. Calcium and vitamin D supplements reduce tooth loss in the elderly. Am J Med 2001;111:452-6
49. Abrahamsen B, Masud T, Avenell A, et al. Vitamin D given with calcium reduces mortality: Patient level analysis of 28 700 patients from five European vitamin D fracture prevention trials. J Bone Miner Res 24 (Suppl 1). Abstract A09002426. Available at: Http://www.asbmr.org/Meetings/AnnualMeeting/ Abstracts09.aspx [Last accessed 30 December 2009]
50. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009;CD000227
51. Geleijnse JM. Vitamin D and the prevention of hypertension and cardiovascular diseases: A review of the current evidence. Am J Hypertens 2011; 24:253-62
52. Wang L, Manson JE, Song Y, et al. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152:315-23
53. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: Randomised controlled trial. BMJ 2008;336:262-6
54. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. BMJ 2010;341:c3691
55. Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011;26:35-41
56. Reid IR, Bolland MJ, Avenell A, et al. Cardiovascular effects of calcium supplementation. Osteoporos Int 2011;22:1649-58
57. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997;94: 14105-10
58. Clemett D, Spencer CM. Raloxifene: A review of its use in postmenopausal osteoporosis. Drugs 2000;60:379-411
59. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45
60. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Fouryear results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
61. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44
62. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41
63. Ding H, Field TS. Bone health in postmenopausal women with early breast cancer: How protective is tamoxifen? Cancer Treatment Reviews 2007;33: 506-13
64. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
65. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-52
66. European Medicines Agency. Raloxifene. Summary of product characteristics. Available at: Http://www.emea.europa.eu [Last accessed 4 January 2010]
67. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006;12:5242-7
68. Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 2006;97:520-7
69. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004;104:837-44
70. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-52
71. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
72. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24
73. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
74. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
75. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
76. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
77. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
78. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
79. Felsenberg D, Recker RR, Kenwright A, et al. Suppression of bone turnover markers with monthly oral ibandronate is sustained over 5 years. Abstract P477. Osteoporos Int 2010;21(Suppl 1):S194. Abstract
80. Colon-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: Enough of a good thing. JAMA 2006;296: 2968-9
81. Watts NB, Diab DL. Long-term use of bisphosphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65
82. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-9
83. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial. J Bone Miner Res 2010;25:976-82
84. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501
85. Black DM, Reid IR, Cauley J, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON Pivotal fracture trial. Abstract OPC11. Bone 2011;48:S91. Abstract
86. Pazianas M, Cooper C, Ebetino FH, et al. Long-term treatment with bisphospohnates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010;6:325-43
87. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6
88. European Medicines Agency. Zoledronic acid. Summary of product characteristics. Available at: Http://www.emea.europa.eu [Last accessed 4 January 2010]
89. Grosso A, Douglas I, Hingorani A, et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: A self-controlled case-series safety analysis. PLoS One 2009;4:e4720
90. Kim SY, Kim MJ, Cadarette SM, et al. Bisphosphonates and risk of atrial fibrillation: A meta-analysis. Arthritis Res Ther 2010;12:R30
91. Bhuriya R, Singh M, Molnar J, et al. Bisphosphonate use in women and the risk of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol 2010;142:213-17
92. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf 2009;32:219-28
93. Mak A, Cheung MW, Ho RC, et al. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 2009;10:113
94. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
95. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102
96. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-81
97. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-9
98. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7
99. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int 2009;20:1353-62
100. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50
101. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 2007; 89:349-53
102. European Medicines Agency. Alendronate. Summary of product characteristics. Available at: Http://www.emea.europa.eu [Last accessed 19 January 2010]
103. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-71
104. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010;86:421-35
105. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
106. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50
107. Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after longterm treatment with bisphosphonates: A European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22:373-90
108. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94
109. Rizzoli R, Bruyere O, Cannata-Andia JB, et al. Management of osteoporosis in the elderly. Curr Med Res Opin 2009;25:2373-87
110. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
111. Unnanuntana A, Ashfaq T, Ton QV, et al. The effect of long-term alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res 2012;470:291-8
112. European Medicines Agency. EMEA 2010 Priorities for Drug Safety Research. Long-term adverse skeletal effects of bisphosphonates. Available at: Http://www.ema.europa.eu/pdfs/human/phv/49371109en.pdf [Last accessed 19 March 2010]
113. Cummings SR, San Martin J, Mac Clung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
114. Miller PD, Bolognese M, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43:222-9
115. Papapoulos S, Man Z, Mellstrom D, et al. Five-year denosumab treatment of postmenopausal women with osteoporosis: Results from the first two years of the FREEDOM trial extension. Abstract OC25. Osteoporos Int 2011;22(Suppl 1):S107. Abstract
116. Marie PJ. Strontium ranelate: New insights into its dual mode of action. Bone 2007;40:S5-S8
117. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
118. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
119. Seeman E, Boonen S, Borgström F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life years in women over 80 years of age. Bone 2010;46:1038-42
120. European Medicines Agency. Strontium ranelate. Summary of product characteristics. Available at: Http://www.emea.europa.eu [Last accessed 3 June 2010]
121. Bolland MJ, Grey AB, Gamble GD, et al. Effect of osteoporosis treatment on mortality: A meta-analysis. J Clin Endocrinol Metab 2010;95: 1174-81
122. Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011;96:1006-14
123. Grady D, Cauley JA, Stock JL, et al. Effect of raloxifene on all-cause mortality. Am J Med 2010;123:469-7
124. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: A review of the evidence. Expert Opin Pharmacother 2009;10:2303-15
125. Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-31
126. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8
127. Kanis JA, Cooper C, Hiligsmann M, et al. Partial adherence: A new perspective on health economic assessment in osteoporosis. Osteoporos Int 2011;22:2565-73
128. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
129. Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
130. Body JJ. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002;30:75S-9S
131. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 2001;285:2891-7
132. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: Scientific review. JAMA 2002;288:872-81